News for Agent

Daily business news: funding, M&A, launches

Partnerships

Bionsight and Astellas Begin Joint Research on First-in-Class Autoimmune Therapy

By ·

Key takeaways

  • Bionsight and Astellas Pharma entered a global R&D collaboration agreement that took effect in November 2026.
  • Bionsight will lead AI-driven molecular design, target validation on its Javelin platform and lead optimization, while Astellas provides data and development guidance.
  • The project was selected for the Global Collaboration R&D track of the 2026 SME Technology Innovation Development Program run by TIPA.

Bionsight has entered a global R&D collaboration agreement with Astellas Pharma and begun joint research toward a first-in-class therapy for autoimmune disorders, the company said in a November 19 announcement carried by EIN Presswire. The agreement took effect in November 2026.

How the Bionsight and Astellas Work Is Split

Bionsight will lead the project, overseeing AI-driven molecular design, target validation using its proprietary Javelin platform and lead optimization. Astellas will contribute its data and expertise and provide development guidance and support under the agreement.

The companies plan to develop a therapy that targets the innate immune pathway, working through a different mechanism from existing treatments. The collaboration builds on Bionsight's platform, which combines AI molecular design and chemoproteomics.

Javelin analyzes how a drug interacts with more than 7,000 proteins at once without chemically modifying the drug and pinpoints the exact sites where the drug binds, according to the announcement. Bionsight says the platform shows early in development which proteins a drug actually acts on in the body, improving the accuracy of target discovery and lead optimization.

"This partnership with Astellas represents a significant milestone for Bionsight as we translate our platform technologies into tangible global drug development programs," said Heejung Yang, CEO of Bionsight. "By combining our AI-chemoproteomics capabilities with Astellas' global expertise, we aim to deliver innovative treatments for patients with autoimmune disorders."

The project was selected for the Global Collaboration R&D track of the 2026 SME Technology Innovation Development Program, run by the Korea Technology and Information Promotion Agency for SMEs (TIPA).

Bionsight's Funding and Platform Record

Bionsight's funding records on akta.pro company records show a Series A of 55 billion KRW from SV Investment, DSC Investment and Schmidt, after a Pre-Series A in February 2021 backed by DSC Investment and Schmidt. The same records list a 2023-08 Series A of $4.1 million with 3 investors and a 2021-05 seed round with 2 investors.

The records also show Bionsight was selected in 2024 for the Scale-up TIPS program run by South Korea's Ministry of SMEs and Startups, receiving up to 11.4 billion KRW over 3 years for Javelin platform development, and for the Post-TIPS 2nd program with 300 million KRW in government support. In 2023 it was selected for Takeda's COCKPI-T Funding Program, which provides one year of research support, access to Takeda's research network and funding.

AI Drug Discovery Deals Elsewhere

Funnel Biosciences announced a strategic research collaboration with Third Rock Ventures on biopharmaceutical development using its AI antibody platform, a deal including platform usage fees and potential payments up to approximately $2.16 billion, The Pharma Letter reported on November 10, 2026.

Fauna Bio announced a second target designation in its obesity discovery collaboration with Eli Lilly on November 11, 2026, a milestone triggering additional payments under an agreement signed in December 2023 that includes up to $494 million in milestone payments and royalties, Business Wire Blog reported.

Ascidian Therapeutics and Exegenesis Bio announced a strategic agreement combining RNA exon editing with AI-enabled AAV capsid engineering on November 12, 2026, with specific indications and financial terms not disclosed, PR Newswire reported.

Companies in this story

Sources

Machine-readable: Markdown · JSON